Heidi L. Wagner - 11 Aug 2026 Form 4 Insider Report for Wave Life Sciences, Inc. (WVE)

Reporting relationship: Director
Issuer ticker: WVE
Reported as of: 11 Aug 2026
Net transaction value: -$42,070
SEC form: 4
Accepted by SEC: 13 Aug 2026, 21:00:10 UTC
Prior SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Heidi L. Wagner

Key filing fact

Heidi L. Wagner filed Form 4 for Wave Life Sciences, Inc. (WVE) on 13 Aug 2026.

Key facts

This page summarizes Heidi L. Wagner's Form 4 filing for Wave Life Sciences, Inc. (WVE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Aug 2026, 21:00.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: -$42,070.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001655029 Primary reporting owner

Wagner Heidi L

Relationship: Director
Address: C/O WAVE LIFE SCIENCES, INC.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Heidi L. Wagner
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,000
Change %: +16%
Price: $5.97^*
Shares after: 51,930
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

WVE transaction

Common Stock

Sale

Transaction value: $42,070
Shares: -7,000
Change %: -13%
Price: $6.01
Shares after: 44,930
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WVE transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -7,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 7,000
Exercise price: $5.97
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

Footnote F2

These stock options are fully vested.

SEC remarks

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney